• PDF / 207,503 Bytes
• 20 Pages / 504.57 x 720 pts Page_size
• 39 Downloads / 206 Views

DOWNLOAD

REPORT

Clin Pharmacokinet 2004; 43 (5): 291-310 0312-5963/04/0005-0291/$31.00/0 © 2004 Adis Data Information BV. All rights reserved.

Pharmacokinetic Enhancement of Protease Inhibitor Therapy Jennifer R. King,1 Heather Wynn,2 Richard Brundage3 and Edward P. Acosta1 1 2 3

Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA Department of Experimental and Clinical Pharmacology, School of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA

Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291 1. Rationale for Protease Inhibitor Enhancement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292 2. Dual Protease Inhibitor Regimens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293 2.1 Saquinavir and Ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293 2.1.1 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293 2.1.2 Clinical Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295 2.2 Indinavir and Ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296 2.2.1 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296 2.2.2 Clinical Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298 2.3 Amprenavir and Ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298 2.3.1 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298 2.3.2 Clinical Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 2.4 Lopinavir/Ritonavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 2.4.1 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 2.4.2 Clinical Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 2.5 Atazanavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Recommend Documents

Protease Inhibitor Use in COVID-19

164 11 642KB

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19

153 3 3MB

The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quali

130 71 541KB

First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center

142 81 667KB

Protease

180 94 126KB

Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral the

133 68 260KB

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

145 89 996KB

Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease

167 100 4MB

Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy

151 62 297KB

Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA

143 81 2MB

Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Predictors of Nonresponse

169 78 771KB

Evolutionary Multi-objective Design of SARS-CoV-2 Protease Inhibitor Candidates

145 3 46MB